nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—CYP2C19—Methimazole—Graves' disease	0.226	0.325	CbGbCtD
Gefitinib—CYP2C9—Methimazole—Graves' disease	0.188	0.27	CbGbCtD
Gefitinib—CYP2D6—Methimazole—Graves' disease	0.172	0.247	CbGbCtD
Gefitinib—CYP3A4—Methimazole—Graves' disease	0.109	0.157	CbGbCtD
Gefitinib—Interstitial pneumonia—Propylthiouracil—Graves' disease	0.015	0.164	CcSEcCtD
Gefitinib—SBK1—eye—Graves' disease	0.0119	0.0658	CbGeAlD
Gefitinib—Interstitial lung disease—Propylthiouracil—Graves' disease	0.0103	0.112	CcSEcCtD
Gefitinib—SBK1—pituitary gland—Graves' disease	0.00885	0.0488	CbGeAlD
Gefitinib—CHEK2—pituitary gland—Graves' disease	0.00771	0.0425	CbGeAlD
Gefitinib—CHEK2—adipose tissue—Graves' disease	0.00768	0.0424	CbGeAlD
Gefitinib—SBK1—thyroid gland—Graves' disease	0.00763	0.0421	CbGeAlD
Gefitinib—CHEK2—thyroid gland—Graves' disease	0.00665	0.0367	CbGeAlD
Gefitinib—ERBB3—connective tissue—Graves' disease	0.00612	0.0338	CbGeAlD
Gefitinib—MKNK2—eye—Graves' disease	0.00604	0.0333	CbGeAlD
Gefitinib—MKNK1—eye—Graves' disease	0.00597	0.0329	CbGeAlD
Gefitinib—Hepatic failure—Propylthiouracil—Graves' disease	0.00587	0.0641	CcSEcCtD
Gefitinib—MKNK2—connective tissue—Graves' disease	0.00582	0.0321	CbGeAlD
Gefitinib—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.00559	0.0611	CcSEcCtD
Gefitinib—EGFR—adipose tissue—Graves' disease	0.00506	0.0279	CbGeAlD
Gefitinib—CSNK1E—pituitary gland—Graves' disease	0.00489	0.027	CbGeAlD
Gefitinib—CSNK1E—adipose tissue—Graves' disease	0.00487	0.0269	CbGeAlD
Gefitinib—IRAK4—pituitary gland—Graves' disease	0.00481	0.0266	CbGeAlD
Gefitinib—IRAK4—adipose tissue—Graves' disease	0.00479	0.0264	CbGeAlD
Gefitinib—ERBB3—adipose tissue—Graves' disease	0.0047	0.0259	CbGeAlD
Gefitinib—MKNK2—pituitary gland—Graves' disease	0.00448	0.0247	CbGeAlD
Gefitinib—MKNK2—adipose tissue—Graves' disease	0.00447	0.0246	CbGeAlD
Gefitinib—IRAK1—adipose tissue—Graves' disease	0.00447	0.0246	CbGeAlD
Gefitinib—MKNK1—pituitary gland—Graves' disease	0.00443	0.0244	CbGeAlD
Gefitinib—MKNK1—adipose tissue—Graves' disease	0.00441	0.0243	CbGeAlD
Gefitinib—EGFR—thyroid gland—Graves' disease	0.00438	0.0242	CbGeAlD
Gefitinib—Hepatitis—Methimazole—Graves' disease	0.00429	0.0469	CcSEcCtD
Gefitinib—CSNK1E—thyroid gland—Graves' disease	0.00421	0.0233	CbGeAlD
Gefitinib—IRAK4—thyroid gland—Graves' disease	0.00415	0.0229	CbGeAlD
Gefitinib—ERBB3—thyroid gland—Graves' disease	0.00407	0.0224	CbGeAlD
Gefitinib—MKNK2—thyroid gland—Graves' disease	0.00387	0.0213	CbGeAlD
Gefitinib—IRAK1—thyroid gland—Graves' disease	0.00387	0.0213	CbGeAlD
Gefitinib—MKNK1—thyroid gland—Graves' disease	0.00382	0.0211	CbGeAlD
Gefitinib—Alopecia—Methimazole—Graves' disease	0.00379	0.0414	CcSEcCtD
Gefitinib—Haemoglobin—Propylthiouracil—Graves' disease	0.00367	0.0401	CcSEcCtD
Gefitinib—Hepatitis—Propylthiouracil—Graves' disease	0.00365	0.0399	CcSEcCtD
Gefitinib—Haemorrhage—Propylthiouracil—Graves' disease	0.00365	0.0399	CcSEcCtD
Gefitinib—STK10—adipose tissue—Graves' disease	0.00363	0.02	CbGeAlD
Gefitinib—MAP2K5—pituitary gland—Graves' disease	0.00326	0.018	CbGeAlD
Gefitinib—MAP2K5—adipose tissue—Graves' disease	0.00324	0.0179	CbGeAlD
Gefitinib—Alopecia—Propylthiouracil—Graves' disease	0.00322	0.0352	CcSEcCtD
Gefitinib—STK10—thyroid gland—Graves' disease	0.00314	0.0173	CbGeAlD
Gefitinib—Thrombocytopenia—Methimazole—Graves' disease	0.00298	0.0326	CcSEcCtD
Gefitinib—MAP2K5—thyroid gland—Graves' disease	0.00281	0.0155	CbGeAlD
Gefitinib—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00254	0.0277	CcSEcCtD
Gefitinib—Urticaria—Methimazole—Graves' disease	0.00242	0.0265	CcSEcCtD
Gefitinib—Body temperature increased—Methimazole—Graves' disease	0.00241	0.0263	CcSEcCtD
Gefitinib—Pruritus—Methimazole—Graves' disease	0.00216	0.0236	CcSEcCtD
Gefitinib—Urticaria—Propylthiouracil—Graves' disease	0.00206	0.0225	CcSEcCtD
Gefitinib—Body temperature increased—Propylthiouracil—Graves' disease	0.00205	0.0224	CcSEcCtD
Gefitinib—Vomiting—Methimazole—Graves' disease	0.00194	0.0212	CcSEcCtD
Gefitinib—Rash—Methimazole—Graves' disease	0.00192	0.021	CcSEcCtD
Gefitinib—Dermatitis—Methimazole—Graves' disease	0.00192	0.021	CcSEcCtD
Gefitinib—Pruritus—Propylthiouracil—Graves' disease	0.00183	0.02	CcSEcCtD
Gefitinib—Nausea—Methimazole—Graves' disease	0.00181	0.0198	CcSEcCtD
Gefitinib—Vomiting—Propylthiouracil—Graves' disease	0.00165	0.018	CcSEcCtD
Gefitinib—Rash—Propylthiouracil—Graves' disease	0.00163	0.0179	CcSEcCtD
Gefitinib—Dermatitis—Propylthiouracil—Graves' disease	0.00163	0.0178	CcSEcCtD
Gefitinib—ABCG2—pituitary gland—Graves' disease	0.00158	0.00874	CbGeAlD
Gefitinib—ABCG2—adipose tissue—Graves' disease	0.00158	0.00871	CbGeAlD
Gefitinib—Nausea—Propylthiouracil—Graves' disease	0.00154	0.0168	CcSEcCtD
Gefitinib—CYP1A1—adipose tissue—Graves' disease	0.0015	0.00827	CbGeAlD
Gefitinib—CYP3A5—adipose tissue—Graves' disease	0.00146	0.00808	CbGeAlD
Gefitinib—ABCG2—thyroid gland—Graves' disease	0.00137	0.00754	CbGeAlD
Gefitinib—CYP1A1—thyroid gland—Graves' disease	0.0013	0.00715	CbGeAlD
Gefitinib—ABCB1—pituitary gland—Graves' disease	0.000781	0.00431	CbGeAlD
Gefitinib—ABCB1—adipose tissue—Graves' disease	0.000778	0.00429	CbGeAlD
Gefitinib—ABCB1—thyroid gland—Graves' disease	0.000673	0.00372	CbGeAlD
Gefitinib—IRAK1—IL-1 signaling pathway—IL1B—Graves' disease	0.000223	0.00671	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by Interleukins—IL2RA—Graves' disease	0.000221	0.00664	CbGpPWpGaD
Gefitinib—EGFR—Thromboxane A2 receptor signaling—ICAM1—Graves' disease	0.000217	0.00651	CbGpPWpGaD
Gefitinib—CSNK1E—Circadian rythm related genes—FAS—Graves' disease	0.000213	0.00641	CbGpPWpGaD
Gefitinib—IRAK4—Toll-like Receptor Signaling Pathway—IL1B—Graves' disease	0.000205	0.00616	CbGpPWpGaD
Gefitinib—MAP2K5—Cardiac Hypertrophic Response—TNF—Graves' disease	0.000202	0.00606	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—FASLG—Graves' disease	0.000202	0.00606	CbGpPWpGaD
Gefitinib—ERBB3—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—Graves' disease	0.0002	0.00602	CbGpPWpGaD
Gefitinib—IRAK4—Signaling by Interleukins—IL1B—Graves' disease	0.000196	0.00589	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—FAS—Graves' disease	0.000195	0.00584	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000193	0.0058	CbGpPWpGaD
Gefitinib—ERBB3—DAP12 interactions—HLA-B—Graves' disease	0.000191	0.00573	CbGpPWpGaD
Gefitinib—MKNK1—MAPK Signaling Pathway—IL1B—Graves' disease	0.000185	0.00556	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—HLA-DQB1—Graves' disease	0.000185	0.00555	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—CXCL10—Graves' disease	0.00018	0.00541	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000172	0.00517	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—IFIH1—Graves' disease	0.000166	0.00498	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—HLA-B—Graves' disease	0.000166	0.00498	CbGpPWpGaD
Gefitinib—EGFR—SHP2 signaling—IFNG—Graves' disease	0.00016	0.00482	CbGpPWpGaD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—IL1B—Graves' disease	0.00016	0.00481	CbGpPWpGaD
Gefitinib—EGFR—DAP12 signaling—HLA-E—Graves' disease	0.000159	0.00476	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—IL2RA—Graves' disease	0.000155	0.00467	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-E—Graves' disease	0.000155	0.00464	CbGpPWpGaD
Gefitinib—MKNK1—Disease—B3GNT2—Graves' disease	0.000154	0.00463	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—HLA-A—Graves' disease	0.000154	0.00462	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—HLA-E—Graves' disease	0.000149	0.00448	CbGpPWpGaD
Gefitinib—IRAK4—Toll-like Receptor Signaling Pathway—TNF—Graves' disease	0.000149	0.00447	CbGpPWpGaD
Gefitinib—MAP2K5—MicroRNAs in cardiomyocyte hypertrophy—TNF—Graves' disease	0.000144	0.00432	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—HLA-E—Graves' disease	0.000144	0.00431	CbGpPWpGaD
Gefitinib—EGFR—Regulation of Telomerase—IFNG—Graves' disease	0.000141	0.00424	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	0.00014	0.00422	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—CD40—Graves' disease	0.00014	0.00421	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—CTLA4—Graves' disease	0.000138	0.00415	CbGpPWpGaD
Gefitinib—IRAK1—Toll-like Receptor Signaling Pathway—IL1B—Graves' disease	0.000136	0.00409	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—ICAM1—Graves' disease	0.000135	0.00405	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—ICAM1—Graves' disease	0.000135	0.00404	CbGpPWpGaD
Gefitinib—MKNK1—MAPK Signaling Pathway—TNF—Graves' disease	0.000134	0.00404	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—IFIH1—Graves' disease	0.000132	0.00397	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—HLA-E—Graves' disease	0.000131	0.00392	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by Interleukins—IL1B—Graves' disease	0.00013	0.00391	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000125	0.00375	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.000125	0.00375	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-DQB1—Graves' disease	0.000123	0.00368	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000122	0.00366	CbGpPWpGaD
Gefitinib—EGFR—Direct p53 effectors—FAS—Graves' disease	0.000121	0.00363	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—B3GNT2—Graves' disease	0.00012	0.0036	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—ICAM1—Graves' disease	0.000119	0.00359	CbGpPWpGaD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—TNF—Graves' disease	0.000116	0.00349	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—IL1B—Graves' disease	0.000114	0.00342	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	0.000114	0.00342	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—IFIH1—Graves' disease	0.00011	0.00331	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-B—Graves' disease	0.00011	0.00331	CbGpPWpGaD
Gefitinib—CHEK2—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.00011	0.00331	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—ICAM1—Graves' disease	0.00011	0.00329	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000109	0.00327	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—FASLG—Graves' disease	0.000108	0.00325	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—IL1B—Graves' disease	0.000106	0.00319	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—HLA-B—Graves' disease	0.000106	0.00319	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—FAS—Graves' disease	0.000104	0.00314	CbGpPWpGaD
Gefitinib—ABCG2—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.000104	0.00313	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—HLA-E—Graves' disease	0.000104	0.00313	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL2RA—Graves' disease	0.000103	0.0031	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—IFNG—Graves' disease	0.000103	0.00308	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—IFNG—Graves' disease	0.000102	0.00308	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—HLA-B—Graves' disease	0.000102	0.00307	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-A—Graves' disease	0.000102	0.00306	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—FASLG—Graves' disease	0.0001	0.003	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HLA-E—Graves' disease	0.0001	0.003	CbGpPWpGaD
Gefitinib—IRAK1—Toll-like Receptor Signaling Pathway—TNF—Graves' disease	9.89e-05	0.00297	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	9.78e-05	0.00294	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD40—Graves' disease	9.77e-05	0.00293	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IFIH1—Graves' disease	9.67e-05	0.0029	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—FAS—Graves' disease	9.64e-05	0.0029	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CTLA4—Graves' disease	9.63e-05	0.00289	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IL2RA—Graves' disease	9.59e-05	0.00288	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—HLA-A—Graves' disease	9.48e-05	0.00285	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	9.43e-05	0.00283	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	9.32e-05	0.0028	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—HLA-B—Graves' disease	9.3e-05	0.00279	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—IL1B—Graves' disease	9.15e-05	0.00275	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—IL1B—Graves' disease	9.14e-05	0.00274	CbGpPWpGaD
Gefitinib—ERBB3—Disease—B3GNT2—Graves' disease	9.13e-05	0.00274	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—IFNG—Graves' disease	9.09e-05	0.00273	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—ICAM1—Graves' disease	8.95e-05	0.00269	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TSHR—Graves' disease	8.94e-05	0.00269	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—ICAM1—Graves' disease	8.7e-05	0.00261	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HLA-E—Graves' disease	8.67e-05	0.0026	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	8.66e-05	0.0026	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—IFNG—Graves' disease	8.33e-05	0.0025	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—TNF—Graves' disease	8.26e-05	0.00248	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—IL1B—Graves' disease	8.11e-05	0.00243	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—GC—Graves' disease	7.97e-05	0.00239	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HLA-DQB1—Graves' disease	7.93e-05	0.00238	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	7.9e-05	0.00237	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	7.9e-05	0.00237	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—TNF—Graves' disease	7.72e-05	0.00232	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IFIH1—Graves' disease	7.71e-05	0.00231	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-E—Graves' disease	7.61e-05	0.00228	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD40—Graves' disease	7.43e-05	0.00223	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—IL1B—Graves' disease	7.43e-05	0.00223	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—HLA-B—Graves' disease	7.42e-05	0.00223	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD8A—Graves' disease	7.41e-05	0.00222	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IFIH1—Graves' disease	7.37e-05	0.00221	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CTLA4—Graves' disease	7.33e-05	0.0022	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—GC—Graves' disease	7.27e-05	0.00218	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HLA-B—Graves' disease	7.12e-05	0.00214	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TSHR—Graves' disease	6.96e-05	0.00209	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IFNG—Graves' disease	6.81e-05	0.00204	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—TNF—Graves' disease	6.63e-05	0.00199	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—IFNG—Graves' disease	6.62e-05	0.00199	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HLA-A—Graves' disease	6.6e-05	0.00198	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—GC—Graves' disease	6.53e-05	0.00196	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—GABRA3—Graves' disease	6.43e-05	0.00193	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IFIH1—Graves' disease	6.42e-05	0.00193	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IFNG—Graves' disease	6.32e-05	0.0019	CbGpPWpGaD
Gefitinib—MKNK1—Disease—HLA-A—Graves' disease	6.24e-05	0.00187	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HLA-B—Graves' disease	6.18e-05	0.00185	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—IL1B—Graves' disease	6.11e-05	0.00184	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL1B—Graves' disease	6.07e-05	0.00182	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-E—Graves' disease	6.06e-05	0.00182	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-DQB1—Graves' disease	6.03e-05	0.00181	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HLA-DRB1—Graves' disease	6.03e-05	0.00181	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—GC—Graves' disease	5.95e-05	0.00179	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD40—Graves' disease	5.93e-05	0.00178	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—IL1B—Graves' disease	5.91e-05	0.00177	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—TNF—Graves' disease	5.88e-05	0.00177	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CTLA4—Graves' disease	5.84e-05	0.00175	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HLA-E—Graves' disease	5.8e-05	0.00174	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—ICAM1—Graves' disease	5.79e-05	0.00174	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CXCL10—Graves' disease	5.78e-05	0.00174	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IL1B—Graves' disease	5.64e-05	0.00169	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD8A—Graves' disease	5.63e-05	0.00169	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	5.63e-05	0.00169	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-E—Graves' disease	5.57e-05	0.00167	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CD4—Graves' disease	5.56e-05	0.00167	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TSHR—Graves' disease	5.5e-05	0.00165	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD40—Graves' disease	5.44e-05	0.00163	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-B—Graves' disease	5.42e-05	0.00163	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—TNF—Graves' disease	5.39e-05	0.00162	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CTLA4—Graves' disease	5.36e-05	0.00161	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TSHR—Graves' disease	5.3e-05	0.00159	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GC—Graves' disease	5.25e-05	0.00158	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—TNF—Graves' disease	5.23e-05	0.00157	CbGpPWpGaD
Gefitinib—EGFR—Disease—B3GNT2—Graves' disease	5.09e-05	0.00153	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL2RA—Graves' disease	5.08e-05	0.00152	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-E—Graves' disease	5.05e-05	0.00152	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-A—Graves' disease	5.02e-05	0.00151	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—TSHR—Graves' disease	5e-05	0.0015	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD40—Graves' disease	4.93e-05	0.00148	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	4.93e-05	0.00148	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CTLA4—Graves' disease	4.86e-05	0.00146	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HLA-A—Graves' disease	4.85e-05	0.00146	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-DQB1—Graves' disease	4.81e-05	0.00144	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	4.8e-05	0.00144	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	4.76e-05	0.00143	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-DRB1—Graves' disease	4.59e-05	0.00138	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CXCL10—Graves' disease	4.5e-05	0.00135	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD8A—Graves' disease	4.49e-05	0.00135	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TNF—Graves' disease	4.43e-05	0.00133	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CD4—Graves' disease	4.43e-05	0.00133	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL2RA—Graves' disease	4.42e-05	0.00133	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-DQB1—Graves' disease	4.42e-05	0.00133	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TSHR—Graves' disease	4.41e-05	0.00133	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—ICAM1—Graves' disease	4.4e-05	0.00132	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-B—Graves' disease	4.32e-05	0.0013	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IFIH1—Graves' disease	4.29e-05	0.00129	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—TNF—Graves' disease	4.29e-05	0.00129	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD4—Graves' disease	4.25e-05	0.00128	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HLA-B—Graves' disease	4.13e-05	0.00124	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD8A—Graves' disease	4.12e-05	0.00124	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—TNF—Graves' disease	4.09e-05	0.00123	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL2RA—Graves' disease	4.05e-05	0.00122	CbGpPWpGaD
Gefitinib—MKNK1—Disease—CD4—Graves' disease	4.02e-05	0.00121	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-DQB1—Graves' disease	4e-05	0.0012	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-A—Graves' disease	4e-05	0.0012	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	4e-05	0.0012	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—B3GNT2—Graves' disease	3.98e-05	0.00119	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-B—Graves' disease	3.97e-05	0.00119	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GC—Graves' disease	3.76e-05	0.00113	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD8A—Graves' disease	3.74e-05	0.00112	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HLA-A—Graves' disease	3.7e-05	0.00111	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CD4—Graves' disease	3.69e-05	0.00111	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-A—Graves' disease	3.67e-05	0.0011	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-DRB1—Graves' disease	3.66e-05	0.0011	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-B—Graves' disease	3.6e-05	0.00108	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CXCL10—Graves' disease	3.55e-05	0.00107	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GC—Graves' disease	3.55e-05	0.00107	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—ICAM1—Graves' disease	3.51e-05	0.00105	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL2RA—Graves' disease	3.44e-05	0.00103	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CXCL10—Graves' disease	3.42e-05	0.00103	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-E—Graves' disease	3.38e-05	0.00101	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL2RA—Graves' disease	3.37e-05	0.00101	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-DRB1—Graves' disease	3.36e-05	0.00101	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IFNG—Graves' disease	3.35e-05	0.00101	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-A—Graves' disease	3.33e-05	0.001	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD40—Graves' disease	3.3e-05	0.000991	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CTLA4—Graves' disease	3.25e-05	0.000977	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GC—Graves' disease	3.24e-05	0.000972	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD4—Graves' disease	3.24e-05	0.000972	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CXCL10—Graves' disease	3.23e-05	0.000969	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—ICAM1—Graves' disease	3.22e-05	0.000968	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CD4—Graves' disease	3.13e-05	0.000939	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-DRB1—Graves' disease	3.05e-05	0.000914	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL1B—Graves' disease	2.99e-05	0.000897	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TSHR—Graves' disease	2.95e-05	0.000886	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—ICAM1—Graves' disease	2.92e-05	0.000878	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GC—Graves' disease	2.91e-05	0.000873	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCL10—Graves' disease	2.85e-05	0.000856	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—B3GNT2—Graves' disease	2.85e-05	0.000855	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GC—Graves' disease	2.84e-05	0.000852	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL2RA—Graves' disease	2.72e-05	0.000816	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—B3GNT2—Graves' disease	2.69e-05	0.000808	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-DQB1—Graves' disease	2.68e-05	0.000804	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GC—Graves' disease	2.67e-05	0.000803	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IFNG—Graves' disease	2.67e-05	0.000802	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GC—Graves' disease	2.65e-05	0.000796	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL2RA—Graves' disease	2.62e-05	0.000786	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD4—Graves' disease	2.58e-05	0.000775	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD8A—Graves' disease	2.5e-05	0.000751	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IL2RA—Graves' disease	2.48e-05	0.000744	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL2RA—Graves' disease	2.47e-05	0.000741	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CD4—Graves' disease	2.47e-05	0.00074	CbGpPWpGaD
Gefitinib—ALB—Metabolism—B3GNT2—Graves' disease	2.45e-05	0.000737	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-B—Graves' disease	2.41e-05	0.000722	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL1B—Graves' disease	2.38e-05	0.000715	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CD4—Graves' disease	2.38e-05	0.000715	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD4—Graves' disease	2.37e-05	0.000711	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL2RA—Graves' disease	2.25e-05	0.000677	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-A—Graves' disease	2.23e-05	0.000669	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IFNG—Graves' disease	2.22e-05	0.000668	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—B3GNT2—Graves' disease	2.2e-05	0.000661	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL2RA—Graves' disease	2.18e-05	0.000654	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—B3GNT2—Graves' disease	2.15e-05	0.000645	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD4—Graves' disease	2.15e-05	0.000645	CbGpPWpGaD
Gefitinib—EGFR—Disease—HLA-A—Graves' disease	2.06e-05	0.000618	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-DRB1—Graves' disease	2.04e-05	0.000611	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—B3GNT2—Graves' disease	2.03e-05	0.000608	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	2.02e-05	0.000607	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—B3GNT2—Graves' disease	2.01e-05	0.000603	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL1B—Graves' disease	1.98e-05	0.000596	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ICAM1—Graves' disease	1.95e-05	0.000587	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL10—Graves' disease	1.91e-05	0.000573	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TNF—Graves' disease	1.87e-05	0.000562	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GC—Graves' disease	1.75e-05	0.000525	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IFNG—Graves' disease	1.49e-05	0.000447	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2RA—Graves' disease	1.46e-05	0.000438	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD4—Graves' disease	1.44e-05	0.000431	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1B—Graves' disease	1.33e-05	0.000398	CbGpPWpGaD
Gefitinib—EGFR—Disease—CD4—Graves' disease	1.33e-05	0.000398	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—B3GNT2—Graves' disease	1.32e-05	0.000398	CbGpPWpGaD
